Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral health assessment during gender-affirming hormone treatment
NL-OMON23787Completed
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of testosterone in gender dysphoria (GD), sponsored by None. Primary endpoint: Effects of gender-affirming hormone therapy on oral health status. Started Oct 2020; status: completed.
02
Drugs
testosterone
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NL-OMON23787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23787.